Brief: Freeline Targets Initiation Of Dose Confirmation Trial By End Of 2021 For FLT180a Hemophilia B Program

Freeline Therapeutics Holdings

08/02/2021 12:36

Feb 8 (Reuters) - Freeline Therapeutics Holdings PLC
 FRLN.O :
    * FREELINE THERAPEUTICS UPDATES CLINICAL DEVELOPMENT PLAN
FOR ITS
FLT180A HEMOPHILIA B PROGRAM
    * FREELINE THERAPEUTICS HOLDINGS PLC - TARGETING INITIATION
OF
DOSE CONFIRMATION TRIAL BY END OF 2021 WITH DATA READOUT BY END
OF 2022
    * FREELINE THERAPEUTICS HOLDINGS - INITIATION OF PHASE 3
PIVOTAL
TRIAL TARGETED BY MID-2023, WITH DATA READOUT AND BLA FILING
TARGETED BY END OF 2024

Source text for Eikon:  ID:nGNX5qVghV 
Further company coverage:  FRLN.O 

 ((Reuters.Briefs@thomsonreuters.com;))